Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
    • Facilities
  • Therapeutic Areas Overview
    • Central Nervous System
      • Fibromyalgia
      • Posttraumatic Stress Disorder
      • Long Covid
      • Cocaine Intoxication
      • Migraine
      • Depression
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • COVID-19
      • Monkeypox
      • Smallpox
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
      • TNX-601 ER
      • TNX-1300
      • TNX-1900
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-1850
      • TNX-801
      • TNX-3600
    • Rare Disease
      • TNX-2900
    • Scientific Presentations
    • Expanded Access Policy
  • Clinical Trials
  • News & Events
    • Tonix in the News
    • Press Releases
    • Investor Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Tonix is enrolling in a Phase 3 study for Fibromyalgia, and Phase 2 studies for Long COVID, Chronic Migraine, and Major Depressive Disorder. Please visit Clinical Trials.

Multimedia

Investors

Investors

  • Overview
  • News & Events
    • Tonix in the News
    • Press Releases
    • IR Events
    • Email Alerts
    • Op-Eds
  • Presentations
  • Multimedia
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
Dr. Seth Lederman joins the Becker’s Panel to discuss the future of value in biopharma - The Becker’s Panel - June 10, 2021
Jun 10, 2021

Dr. Seth Lederman joins the Becker’s Panel to discuss the future of value in biopharma - The Becker’s Panel - June 10, 2021

Dr. Seth Lederman discusses T Cell Immunity and COVID-19 on Technology Networks
Apr 28, 2021

Dr. Seth Lederman discusses T Cell Immunity and COVID-19 on Technology Networks

Dr. Seth Lederman interviewed by Christine Corrado of Proactive to discuss the preliminary results of its COVID-19 vaccine candidate
Mar 29, 2021

Dr. Seth Lederman interviewed by Christine Corrado of Proactive to discuss the preliminary results of its COVID-19 vaccine candidate

Dr. Seth Lederman spoke to Proactive on the group's 2020 financial results and update on its second Phase 3 study of fibromyalgia.
Mar 29, 2021

Dr. Seth Lederman spoke to Proactive on the group's 2020 financial results and update on its second Phase 3 study of fibromyalgia.

Dr. Seth Lederman interviewed by Christine Corrado of Proactive to discuss Tonix’s second collaboration with Massachusetts General Hospital
Jan 11, 2021

Dr. Seth Lederman interviewed by Christine Corrado of Proactive to discuss Tonix’s second collaboration with Massachusetts General Hospital

Dr. Seth Lederman interviewed on ABC FOX Montana to discuss highlights of Tonix’s planned vaccine manufacturing facility in Hamilton, MT
Jan 6, 2021

Dr. Seth Lederman interviewed on ABC FOX Montana to discuss highlights of Tonix’s planned vaccine manufacturing facility in Hamilton, MT

Dr. Seth Lederman interviewed by Christine Corrado of Proactive Investors to discuss the positive Phase 3 results from its fibromyalgia trial using TNX-102 SL
Dec 15, 2020

Dr. Seth Lederman interviewed by Christine Corrado of Proactive Investors to discuss the positive Phase 3 results from its fibromyalgia trial using TNX-102 SL

Covid-19 Is Not Going to Go Away: Tonix Pharmaceuticals CEO
Dec 7, 2020

Covid-19 Is Not Going to Go Away: Tonix Pharmaceuticals CEO

Dr. Seth Lederman interviewed by Christine Corrado of Proactive Investors to discuss the similarities between a circa 1860 U.S. smallpox vaccine and horsepox virus
Dec 4, 2020

Dr. Seth Lederman interviewed by Christine Corrado of Proactive Investors to discuss the similarities between a circa 1860 U.S. smallpox vaccine and horsepox virus

Dr. Seth Lederman interviewed on Contagion Live to discuss its COVID-19 vaccine in development.
Dec 4, 2020

Dr. Seth Lederman interviewed on Contagion Live to discuss its COVID-19 vaccine in development.

Developing a PTSD Therapeutic - Phase 3 Clinical Development
Nov 12, 2020

Developing a PTSD Therapeutic - Phase 3 Clinical Development

Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19
Sep 24, 2020

Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19

Dr. Seth Lederman presents at the Proactive One2One Virtual Event on August 18, 2020
Aug 18, 2020

Dr. Seth Lederman presents at the Proactive One2One Virtual Event on August 18, 2020

Bringing new medicines to market despite subjective endpoints, Seth Lederman
Aug 11, 2020

Bringing new medicines to market despite subjective endpoints, Seth Lederman

Dr. Seth Lederman presents a vaccine tutorial covering the challenges and opportunities of developing a vaccine for COVID-19
Aug 11, 2020

Dr. Seth Lederman presents a vaccine tutorial covering the challenges and opportunities of developing a vaccine for COVID-19

Dr. Seth Lederman interviewed by Christine Corrado of Proactive Investors to discuss strategic partnerships in developing vaccines for COVID-19
Jul 17, 2020

Dr. Seth Lederman interviewed by Christine Corrado of Proactive Investors to discuss strategic partnerships in developing vaccines for COVID-19

Dr. Seth Lederman interviewed by Jane King on New to the Street to discuss Tonix’s portfolio of product candidates to fight COVID-19
Jul 8, 2020

Dr. Seth Lederman interviewed by Jane King on New to the Street to discuss Tonix’s portfolio of product candidates to fight COVID-19

Dr. Seth Lederman interviewed on Bloomberg TV to discuss the goals & timeline for development of TNX-1800, Tonix’s live replicating COVID-19 vaccine candidate.
Jul 8, 2020

Dr. Seth Lederman interviewed on Bloomberg TV to discuss the goals & timeline for development of TNX-1800, Tonix’s live replicating COVID-19 vaccine candidate.

Seth Lederman interviewed by KWTX’s Haley Vyrostek about Tonix’s partnership with Fujifilm Diosynth to manufacture and develop their COVID-19 vaccine candidate, TNX-1800, for clinical trial supply.
Jun 17, 2020

Seth Lederman interviewed by KWTX’s Haley Vyrostek about Tonix’s partnership with Fujifilm Diosynth to manufacture and develop their COVID-19 vaccine candidate, TNX-1800, for clinical trial supply.

Efforts to Manufacture a COVID-19 Vaccine (Podcast)
Jun 9, 2020

Efforts to Manufacture a COVID-19 Vaccine (Podcast)

rss_feed RSS
  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Next Pagearrow_forward
email icon Sign up for Email Alerts
twitter icon linkedin icon facebook icon
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Site Map

© 2023 Tonix Pharmaceuticals Holding Corp.